tiprankstipranks
Advertisement
Advertisement

TRDA Stock Latest News

Entrada Therapeutics price target raised to $23 from $21 at Oppenheimer
The FlyEntrada Therapeutics price target raised to $23 from $21 at Oppenheimer
7d ago
TRDA
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
12d ago
TRDA
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
12d ago
TRDA
Entrada Therapeutics management to meet with Oppenheimer
PremiumThe Fly
Entrada Therapeutics management to meet with Oppenheimer
14d ago
TRDA
Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics
PremiumRatings
Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics
1M ago
TRDA
Entrada Therapeutics price target raised to $19 from $13 at Roth Capital
PremiumThe FlyEntrada Therapeutics price target raised to $19 from $13 at Roth Capital
1M ago
TRDA
Entrada Therapeutics reports Q4 EPS (94c), consensus ($1.24)
Premium
The Fly
Entrada Therapeutics reports Q4 EPS (94c), consensus ($1.24)
2M ago
TRDA
Advancing DMD and DM1 Pipeline Positions Entrada for Multiple Near‑Term Catalysts and Upside Potential
Premium
Ratings
Advancing DMD and DM1 Pipeline Positions Entrada for Multiple Near‑Term Catalysts and Upside Potential
2M ago
TRDA
Entrada Therapeutics: Advancing ENTR-601-44 Positions Platform for Best-in-Class Dystrophin Restoration and Attractive Risk/Reward
PremiumRatings
Entrada Therapeutics: Advancing ENTR-601-44 Positions Platform for Best-in-Class Dystrophin Restoration and Attractive Risk/Reward
2M ago
TRDA
Entrada announces DMC recommends initiation of Cohort 2 in ELEVATE-44-201 study
PremiumThe Fly
Entrada announces DMC recommends initiation of Cohort 2 in ELEVATE-44-201 study
2M ago
TRDA
Entrada Therapeutics initiated with a Buy at Guggenheim
PremiumThe Fly
Entrada Therapeutics initiated with a Buy at Guggenheim
2M ago
TRDA
Entrada Therapeutics initiated with a Buy at Guggenheim
PremiumThe Fly
Entrada Therapeutics initiated with a Buy at Guggenheim
2M ago
TRDA
Entrada Therapeutics initiated with an Outperform at Oppenheimer
PremiumThe FlyEntrada Therapeutics initiated with an Outperform at Oppenheimer
2M ago
TRDA
Entrada Therapeutics: Advancing DMD and DM1 Pipeline with Emerging Ophthalmology Assets Supports Buy Rating and $20 Target
Premium
Ratings
Entrada Therapeutics: Advancing DMD and DM1 Pipeline with Emerging Ophthalmology Assets Supports Buy Rating and $20 Target
3M ago
TRDA
Entrada Therapeutics highlights RNA pipeline progress and outlook
Premium
Company Announcements
Entrada Therapeutics highlights RNA pipeline progress and outlook
3M ago
8K
TRDA
Entrada Therapeutics reports progress across development portfolio
PremiumThe Fly
Entrada Therapeutics reports progress across development portfolio
3M ago
TRDA
Entrada Therapeutics Reports Increased Losses Amid R&D Expansion
PremiumCompany Announcements
Entrada Therapeutics Reports Increased Losses Amid R&D Expansion
5M ago
TRDA
Entrada Therapeutics price target lowered to $13 from $17 at Roth Capital
PremiumThe Fly
Entrada Therapeutics price target lowered to $13 from $17 at Roth Capital
5M ago
TRDA
Promising Outlook for Entrada Therapeutics: Strategic Advancements in DMD and DM1 with Novel EEV Platform
PremiumRatings
Promising Outlook for Entrada Therapeutics: Strategic Advancements in DMD and DM1 with Novel EEV Platform
5M ago
TRDA
Promising Advancements and Strategic Positioning Drive Buy Rating for Entrada Therapeutics Inc.
PremiumRatingsPromising Advancements and Strategic Positioning Drive Buy Rating for Entrada Therapeutics Inc.
5M ago
TRDA
Entrada Therapeutics files $400M mixed securities shelf
Premium
The Fly
Entrada Therapeutics files $400M mixed securities shelf
5M ago
TRDA
Entrada Therapeutics reports Q3 EPS ($1.06), consensus (96c)
Premium
The Fly
Entrada Therapeutics reports Q3 EPS ($1.06), consensus (96c)
5M ago
TRDA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >